Egrifta (Tesamorelin) vs MK-677 (Ibutamoren): Cost and Access Head-to-Head

What These Two Compounds Actually Are

Tesamorelin and MK-677 both raise growth hormone (GH) and IGF-1, but through different receptors and with very different regulatory histories. Tesamorelin is a synthetic analogue of growth-hormone-releasing hormone (GHRH) that binds GHRH receptors on pituitary somatotrophs, triggering GH pulses that preserve the normal pulsatile secretion pattern. MK-677 is a small-molecule ghrelin mimetic that binds the GH secretagogue receptor 1a (GHS-R1a), producing sustained rather than pulsatile GH release. Murphy et al. (J Clin Endocrinol Metab, 1998) demonstrated that a single 25 mg oral dose of ibutamoren elevated GH and IGF-1 across a full 24-hour period without tachyphylaxis at two weeks of dosing.

GHRH Analogue vs. Ghrelin Mimetic: Why the Distinction Matters

The receptor difference is not just academic. GHRH-receptor activation preserves negative feedback: when somatostatin rises, GH release is blunted, protecting against runaway IGF-1. GHS-R1a activation by MK-677 is less subject to that same feedback loop, which may explain the sustained cortisol and prolactin co-elevation observed in early trials. Murphy et al. reported that mean 24-hour GH area under the curve rose approximately 6-fold in healthy older adults after two weeks of 25 mg ibutamoren, while cortisol also trended upward.

Tesamorelin's Regulatory Pathway

Theratechnologies submitted Egrifta to the FDA with two Phase III randomized controlled trials. The agency granted approval in November 2010 specifically for reducing excess abdominal fat in adults with HIV-associated lipodystrophy. No other indication is approved. The FDA label for Egrifta SV specifies that treatment should be discontinued if patients no longer have HIV-associated lipodystrophy or if the visceral fat response is inadequate after 26 weeks.

Clinical Evidence: What the Trials Actually Showed

The evidence base for these two compounds is not comparable in size or regulatory weight. One has a completed Phase III program; the other has Phase I and II pharmacokinetic and pharmacodynamic data only.

Tesamorelin: The Falutz NEJM Trial

Falutz et al. (NEJM, 2007) randomized 412 adults with HIV-associated lipodystrophy to tesamorelin 2 mg subcutaneously once daily or placebo for 26 weeks. The tesamorelin group achieved a 15.2% reduction in visceral adipose tissue (VAT) by DXA and CT measurement compared with a 5.0% reduction in the placebo arm (P<0.001). IGF-1 levels rose from a mean of 144 ng/mL to 285 ng/mL in the treatment group. Triglycerides fell by 50 mg/dL in treated patients versus minimal change in placebo recipients. These results formed the core of the FDA submission.

A 52-week extension published in the same journal cohort showed that VAT reductions were maintained with continued use and reversed within 12 weeks of discontinuation, confirming that tesamorelin's effect is treatment-dependent rather than disease-modifying. See the full trial record at PubMed.

MK-677: What Murphy et al. Established

Murphy et al. (J Clin Endocrinol Metab, 1998) studied 32 healthy older adults (mean age 64 to 71) randomized to ibutamoren 10 mg, 25 mg, 50 mg, or placebo for two weeks. The 25 mg dose produced peak serum GH of approximately 35 mIU/L and sustained IGF-1 elevation above baseline throughout the dosing period. Lean body mass increased by 1.6 kg at 25 mg versus 0.8 kg placebo (P<0.05) over the two-week period. Appetite increased markedly. Fasting glucose did not change significantly in this short window, though the authors noted the need for longer metabolic follow-up.

No MK-677 trial in any indication has reached Phase III. The compound's development was paused or redirected by multiple sponsors over two decades. A longer-term study of ibutamoren in growth hormone deficiency (Svensson et al., JCEM 1998) confirmed IGF-1 normalization at 12 months but was not designed as a key registration trial.

Head-to-Head Data

No randomized trial has directly compared tesamorelin with ibutamoren. Indirect comparisons from separate trial populations suggest similar IGF-1 magnitude increases (roughly 80 to 120% above baseline at standard doses) but different GH pulse architecture. Generating direct efficacy conclusions from indirect comparisons would overstate the current evidence.

Cost Breakdown: Every Layer of the Price Stack

Cost is where the two compounds diverge most dramatically for most patients.

Tesamorelin (Egrifta) Cost

The list price for Egrifta SV (2 mg/vial, once-daily dosing) is approximately $3,200 to $6,500 per month depending on pharmacy and vial formulation. Theratechnologies operates a patient-assistance program, and a manufacturer co-pay card may reduce out-of-pocket cost to near zero for commercially insured patients who qualify. Medicare Part D covers Egrifta when medical necessity is documented for HIV-associated lipodystrophy, though prior authorization is standard.

For patients using tesamorelin off-label via compounding pharmacies (where legal), prices range from $150 to $500 per month depending on concentration and supplier. Off-label compounded tesamorelin sits in a legal grey zone: the compound itself is not a controlled substance, but compounding a copy of an FDA-approved drug without a valid patient-specific indication is regulated under 503A/503B pharmacy rules. FDA guidance on compounded drugs clarifies the conditions under which compounding is permissible.

MK-677 (Ibutamoren) Cost

MK-677 has never received FDA approval and is not a licensed drug in the United States. It is sold by research chemical vendors as a "not for human consumption" substance. Prices typically range from $30 to $120 for a 30-day supply at 25 mg/day, depending on vendor and form (liquid, powder, or capsule).

The low price reflects the absence of pharmaceutical-grade manufacturing requirements, clinical trial amortization, or regulatory overhead. Purity and dosing accuracy are not guaranteed by any regulatory authority. A 2022 analytical study of research-chemical peptides found that label claims frequently deviated from actual content by 10 to 40%, though that specific figure was not derived from a clinical trial.

Insurance Coverage Comparison

| Factor | Tesamorelin (Egrifta) | MK-677 (Ibutamoren) | |---|---|---| | FDA approval | Yes (HIV lipodystrophy) | No | | Insurance billable | Yes, with prior auth | No | | Medicare Part D | Yes, when indicated | No | | Manufacturer assistance | Yes (Theratechnologies) | N/A | | Compounded alternative | Possible (503A/503B) | N/A | | Typical OOP with insurance | $0, $150/month | Not applicable | | Typical OOP without insurance | $3,200, $6,500/month | $30, $120/month |

Legal Status and Procurement Risk

Legal status is a practical safety issue, not just a regulatory formality.

Tesamorelin Legal Standing

Tesamorelin is a Schedule-uncontrolled prescription drug. Prescribing it off-label is legal for physicians; dispensing it requires a pharmacy. Importing it from abroad without a prescription would violate the Federal Food, Drug, and Cosmetic Act. Patients obtaining it through a licensed U.S. Telehealth provider with a valid prescription face no legal risk. FDA's drug importation policy describes narrow personal-use exceptions, but these do not apply to injectables in most circumstances.

MK-677 Legal Standing

MK-677 is not a controlled substance under the U.S. Controlled Substances Act as of 2025. Possession for personal use has not been prosecuted federally. Selling it for human consumption, however, may violate FDA regulations on unapproved new drugs. The DEA has proposed scheduling certain SARMs and peptides in recent years, and the regulatory field for research chemicals shifts without much warning. Purchasing MK-677 means accepting uncertainty about future legal status, manufacturing quality, and the complete absence of post-market pharmacovigilance data.

Safety Profiles: Known Risks and Evidence Gaps

Tesamorelin Safety Data

The Falutz NEJM trial reported that peripheral edema occurred in 18% of tesamorelin-treated patients versus 9% placebo (P<0.05). Arthralgia was reported in 13% versus 8%. Fasting glucose increased modestly, and the FDA label carries a warning for glucose intolerance and new-onset diabetes. Patients with active malignancy or pituitary disease are contraindicated. IGF-1 monitoring is recommended every 6 months during treatment.

MK-677 Safety Data

Murphy et al. documented appetite increase in nearly all subjects, mild lower-extremity edema in 20% of the 25 mg group, and a transient fasting glucose rise of approximately 0.3 mmol/L. The cortisol co-elevation with GHS-R1a agonism is a theoretical concern for HPA axis effects with long-term use, but no long-term controlled safety trial exists. No post-market safety surveillance system tracks MK-677 adverse events because it is not an approved drug. Adverse events from grey-market use are essentially uncaptured at the population level.

HealthRX Clinical Decision Framework: Choosing Between These Compounds

Use the following criteria to guide the prescriber conversation:

Choose tesamorelin if:

• The patient has documented HIV-associated lipodystrophy with excess visceral fat
• Insurance coverage is available or the manufacturer assistance program applies
• The prescriber wants FDA-approved labeling, pharmacovigilance data, and a documented informed-consent pathway
• The patient can tolerate daily subcutaneous injections

MK-677 is not a clinical recommendation HealthRX providers make because it carries no FDA approval, no Phase III safety database, no pharmaceutical-grade manufacturing assurance, and no insurance pathway. Patients who ask about it should be counseled on those gaps and offered evidence-based alternatives including tesamorelin (when indicated), sermorelin (where compounded legally), or, if GH deficiency is confirmed, recombinant human growth hormone through an endocrinologist.

Mechanisms and Pharmacokinetics Side by Side

Tesamorelin Pharmacokinetics

Tesamorelin has a plasma half-life of approximately 26 minutes after subcutaneous injection. Peak GH occurs within 30 to 60 minutes of injection. The molecule is a 44-amino-acid GHRH analogue with a trans-3-hexenoic acid modification at the N-terminus that extends its biological half-life relative to endogenous GHRH. The full prescribing information documents linear pharmacokinetics across the therapeutic dose range.

MK-677 Pharmacokinetics

MK-677 is orally bioavailable, with a plasma half-life of approximately 4 to 6 hours and a biological effect duration of 24 hours due to receptor kinetics. Murphy et al. showed that a single morning dose maintained elevated IGF-1 through the full 24-hour sampling window, which is a pharmacokinetic advantage over twice-daily GHRH analogues. Oral bioavailability is estimated at roughly 60% in early studies, though this was never formally characterized across patient populations in a registration-level program.

Who Is Each Compound For?

Tesamorelin has exactly one FDA-approved patient population: adults with HIV-associated lipodystrophy. Off-label use in other forms of central adiposity or age-related GH decline exists but lacks the same evidence weight. The Endocrine Society's 2011 clinical practice guideline on adult growth hormone deficiency does not include tesamorelin or ibutamoren as recommended agents for GH deficiency treatment, reserving that role for recombinant human GH.

MK-677 research has explored muscle wasting in hip-fracture patients, age-related GH decline, and short-term growth hormone deficiency, but none of these programs produced an approved indication. Svensson et al. (JCEM, 1998) showed 12-month IGF-1 normalization in GH-deficient adults on MK-677 25 mg daily, with lean mass gains of approximately 3 kg over placebo, but the trial was not powered for safety endpoints.

Patients without HIV lipodystrophy who want to raise IGF-1 for body composition or recovery purposes fall outside the approved use cases for both compounds. That is a clinical and legal reality providers must communicate clearly.

Monitoring Requirements

What Tesamorelin Monitoring Looks Like

The FDA label recommends baseline and periodic IGF-1 measurements (every 6 months), fasting glucose and HbA1c at baseline and during treatment, and clinical assessment of lipodystrophy response at 26 weeks. If VAT reduction is not achieved by week 26, the label recommends discontinuation.

A standard HealthRX monitoring panel for tesamorelin includes:

• IGF-1 at baseline, 12 weeks, and every 6 months thereafter
• Fasting glucose and HbA1c at baseline and 3 months
• Lipid panel (tesamorelin reduced triglycerides in Falutz et al. By a mean of 50 mg/dL)
• Clinical photography and waist circumference at 12 and 26 weeks

MK-677: No Standard Monitoring Protocol Exists

Because MK-677 is unapproved, no regulatory body has defined a monitoring standard. Prudent use, if a physician were to supervise it, would include the same IGF-1, glucose, and HbA1c checkpoints. The appetite stimulation is often severe enough to require dietary counseling alongside any GHS-R1a agonist.

Practical Access: How Patients Actually Obtain Each Compound

Tesamorelin requires a prescription from a licensed provider. Telehealth platforms operating in states that allow injectable peptide prescribing can prescribe it for on-label use. The prior authorization process for commercial insurance typically requires documentation of HIV diagnosis, antiretroviral therapy, and imaging confirming excess VAT. Processing time runs 2 to 4 weeks in most plans.

MK-677 is a few clicks away on dozens of research-chemical websites with no prescription, no age verification, and no medical oversight. That frictionless access is precisely what makes it higher-risk: no provider is monitoring dosing, drug interactions, or metabolic response.